Mount Sinai Division of Gastroenterology

Can prevention start on the plate? A meta-analysis of 72 prospective studies links dietary patterns to #CrohnsDisease risk. Findings support the potential for developing diet-based #IBD prevention recommendations and future clinical trials. Read the article here to learn how:
tinyurl.com/4sjf6hcv

Acid reflux impacts about 20% of American adults. What causes it? Gastroesophageal reflux disease (GERD) impacts about 20% of adults in the U.S. Here's what experts want you to know about causes and treatments.

Brijen Shah, MD shares with USA Today that "Acid reflux can be managed by most people if they learn the behavior changes they can make and how to appropriately use over-the-counter medications."

For further insights from Dr. Shah and more info on the topic, read the full article here: rb.gy/k8b0h2

New data from a first-of-its-kind, head-to-head, double blind trial led by Bruce Sands, MD and team shows guselkumab outperforms the leading #Crohns treatment, even in patients who have failed other biologics. This breakthrough sets a new standard in #IBD care.
www.sciencedirect.com/science/arti...

Mount Sinai researchers are launching a study on GLP-1 agonists as a novel gut-healing therapy for Crohn’s disease, shifting focus from inflammation suppression to epithelial repair. Funded by a $3M Helmsley grant. Learn more: reports.mountsinai.org/article/gi20...

Congrats to Palak Rajauria on winning “Best Research Presentation” at this year’s IBD Retreat! Her talk highlights Dr. Ryan Ungaro’s team’s tool that may predict #CrohnsDisease 2 years before diagnosis with 99% specificity.
Read more: wb.md/3ZZ8rk6

Stephanie Gold, MD, and Elizabeth Spencer, MD, discuss their research on trends in the use of GLP-1 receptor agonists in patients with IBD as well as their safety and efficacy in this patient population. Learn more: bit.ly/4dsRN1H

Mount Sinai is proud to present groundbreaking research and clinical insights at #DDW2025.
View the full list of presenters and download our schedule:
icahn.foleon.com/conferences/...

#HereForDDW #WeFindAWay

Congratulations to Dr. Pascale M. White, honored with the inaugural AGA–Pfizer Beacon of Hope Award for her leadership in advancing gender and health equity in GI.

She will be recognized at the #AGA Beacons of Hope Women’s Luncheon at #DDW2025.

🔗 bit.ly/4cztqPk

@amergastroassn.bsky.social

IBDebrief | Icahn School of Medicine

IBDebrief enhances #IBD knowledge for community #gastroenterology providers. Submit cases for expert discussion & join a "Hot Topics in IBD" review. Sessions are on the first Tuesday monthly, 5–6 PM, with in-person & virtual options.
icahn.mssm.edu/about/depart...

Dysregulation of γδ intraepithelial lymphocytes precedes Crohn’s disease–like ileitis Multiple layers of γδ IEL dysregulation and loss of their immunosuppressive capacity occur before the onset of chronic ileitis.

📚NEW #gdTcell PAPER ALERT! Dysregulation of γδ intraepithelial lymphocytes precedes Crohn’s disease–like ileitis | Science Immunology
Bluetorial coming soon!!! #gastrosky #GIsky #IBDsky @nbgolovchenko.bsky.social @squeakyanimal.bsky.social @andrewfong.bsky.social

March is #ColorectalCancerAwarenessMonth. Join Mount Sinai for educational events across the System from 9 AM - 3 PM. Speak with experts, learn about screenings, and take charge of your health. Call Mount Sinai's CHOICE Program at 212-824-7887 to discuss screening options.
#CRC #ColonCancer

A Mount Sinai-led study found that 60% of cholangiocarcinoma samples had high B7-H4 levels, a protein that inhibits T cell immunity and may drive tumor growth. This discovery could lead to new targeted therapies. Learn more: reports.mountsinai.org/article/live...

A first-in-class monoclonal antibody therapy showed promise in a phase 2 trial, inducing remission in ulcerative colitis patients who hadn’t responded to other treatments. The Mount Sinai-led study offers new hope for those not helped by existing therapies. reports.mountsinai.org/article/gast...

Mount Sinai launched a program for Crohn's disease that combines biologic therapy with brain-gut behavior therapy, helping patients build resilience and take control of their disease.

Learn more: reports.mountsinai.org/article/gast...

#CrohnsDisease #IBD #GutHealth #Resilience

a sign that says san francisco is lit up in front of a city skyline ALT: a sign that says san francisco is lit up in front of a city skyline

Wrapping up #CCCongress25 with my favorite session on how we can prevent #IBD before it starts. Excellent talks from @mountsinaigi.bsky.social colleagues Inga Peter & @mehandrulab.bsky.social and Ken Croitoru on the #GEM cohort. 1/n

Health Equity in Action for Liver and Digestive Diseases (HEALD) focuses on health equity initiatives within the Divisions of Gastroenterology and Liver Diseases. It will address disparities in colorectal and liver cancer screening and introduce a dashboard to track health equity. bit.ly/3En3QQy

Mount Sinai’s iNourish program supports Crohn’s & colitis patients with nutrition-focused care & research. A dedicated clinic tackles malnutrition, affecting up to 70% of hospitalized IBD patients. Learn more: bit.ly/4jDlO1u

#IBD #Nutrition #Crohnscolitis #WeFindAWay

Mount Sinai researchers show wearable devices like Apple Watches can predict #IBD flare-ups, enabling continuous, non-invasive monitoring. Learn more: bit.ly/3PSlrlP

#IBD #WearableTech

Join us on Feb 28, 2025, 8 AM–4 PM for the 20th Annual Mount Sinai IBD Consultant’s Course! Explore cutting-edge strategies to improve diagnosis, treatment & care for IBD patients. Learn more & register: bit.ly/4gPq9Ne

#IBD #HealthcareEducation #MountSinai #InflammatoryBowelDisease

The 2025 #Gastroenterology and #GI Surgery Specialty Report is here. Discover how Mount Sinai is advancing care with innovative treatments, groundbreaking research, and a patient-centered approach. Explore our key achievements and vision for the future of GI health. Read the report: bit.ly/40APpzO